252 related articles for article (PubMed ID: 25075079)
1. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
Okegawa T; Higaki M; Matsumoto T; Kase H; Murata A; Noda K; Noda H; Asaoka H; Oshi M; Tomoishi J; Uchida H; Higashihara E; Nutahara K;
Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
[TBL] [Abstract][Full Text] [Related]
2. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
7. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.
Uemura H; Yanagisawa M; Ikeda I; Fujinami K; Iwasaki A; Noguchi S; Noguchi K; Kubota Y;
Int J Clin Oncol; 2013 Jun; 18(3):472-7. PubMed ID: 22491982
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
9. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
[TBL] [Abstract][Full Text] [Related]
10. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
11. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
Izumi K; Mizokami A; Itai S; Shima T; Shigehara K; Miwa S; Maeda Y; Konaka H; Koh E; Namiki M
BJU Int; 2012 Feb; 109(3):394-400. PubMed ID: 21599822
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
13. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
14. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
[TBL] [Abstract][Full Text] [Related]
15. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
16. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T
Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
[TBL] [Abstract][Full Text] [Related]
17. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
[TBL] [Abstract][Full Text] [Related]
19. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
20. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
